Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TetraPhase's Series C

This article was originally published in Start Up

Executive Summary

Anti-infective developer TetraPhase Pharmaceuticals announced June 1 its $45 million Series C financing, with participation from a syndicate of new and existing backers. The financing is one of the richest of the year, just below the April $56 million Series C pulled in by Achaogen, which is also developing antibiotics for drug resistant diseases. And it far exceeds the average Series C financing of $19.77 million raised between January and May of this year.
Advertisement

Related Content

Start-Up Quarterly Statistics, Q2 2010
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2010
Start-Up Quarterly Statistics, Q2 2010
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2010
As Drug-Resistant Microbes Rise, Antibiotic Start-Ups Need Savvy Investors
As Drug-Resistant Microbes Rise, Antibiotic Start-Ups Need Savvy Investors
The Merger/License Dance of AstraZeneca, Forest and Novexel
The Merger/License Dance of AstraZeneca, Forest and Novexel

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091999

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel